Trends in survival from myeloma, 1990-2015: a competing risks analysis

被引:11
|
作者
Sneyd, Mary Jane [1 ]
Gray, Andrew R. [2 ]
Morison, Ian M. [3 ]
机构
[1] Univ Otago, Hugh Adam Canc Epidemiol Unit, Dept Prevent & Social Med, POB 56, Dunedin 9054, New Zealand
[2] Univ Otago, Biostat Ctr, Dunedin, New Zealand
[3] Univ Otago, Dept Pathol, Dunedin, New Zealand
关键词
Myeloma; Survival; Competing risk regression; MULTIPLE-MYELOMA; CELL TRANSPLANTATION; IMPROVEMENT; MORTALITY; OUTCOMES; ENGLAND; YOUNGER; RACE;
D O I
10.1186/s12885-021-08544-7
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
BackgroundMyeloma survival has greatly increased over past decades. We investigated trends in survival over time in New Zealand by age, ethnicity, and geography and thus examined potential inequalities among these population subgroups.MethodsFrom data supplied by the New Zealand Ministry of Health, all new diagnoses of multiple myeloma (ICD-10 code C90) between 1990 and 2016 were extracted, as well as their matched mortality data. Cox's proportional hazards regression and competing risks regression were used to estimate multivariable survival functions.ResultsBetween 1 January 1990 and 1 December 2015, 6642 myeloma cases were registered by the New Zealand Cancer Registry. Although survival from myeloma increased substantially from 1990-1994 to 2010-2015, 5-year survival was still only about 60% in 2010-2015. The greatest improvement in survival was for people aged 60-69years at diagnosis. Using Cox's proportional hazards regression, Maori showed an increased risk of myeloma death but this was predominantly due to differences in competing risks among ethnic groups. Competing risks analysis found the greatest improvement in myeloma survival in Pacific Islanders, and in 2010-2015 Maori had better survival than other ethnicities. Myeloma survival improved significantly over time in all regional health authorities but in all time periods the Central and Southern regions had significantly poorer survival than the Midland region.ConclusionsImprovements in myeloma survival have been unequal across subgroups and regions in New Zealand. Detailed information about utilization of chemotherapeutic agents and transplantation in New Zealand is not available. This information, as well as more detailed hematological data, is essential to further explore the relationships and reasons for differing myeloma survival in population subgroups of New Zealand.
引用
收藏
页数:9
相关论文
共 50 条
  • [31] A note on competing risks in survival data analysis
    J M Satagopan
    L Ben-Porat
    M Berwick
    M Robson
    D Kutler
    A D Auerbach
    [J]. British Journal of Cancer, 2004, 91 : 1229 - 1235
  • [32] A global test for competing risks survival analysis
    Edelmann, Dominic
    Saadati, Maral
    Putter, Hein
    Goeman, Jelle
    [J]. STATISTICAL METHODS IN MEDICAL RESEARCH, 2020, 29 (12) : 3666 - 3683
  • [33] A note on competing risks in survival data analysis
    Satagopan, JM
    Ben-Porat, L
    Berwick, M
    Robson, M
    Kutler, D
    Auerbach, AD
    [J]. BRITISH JOURNAL OF CANCER, 2004, 91 (07) : 1229 - 1235
  • [34] Simulating competing risks data in survival analysis
    Beyersmann, Jan
    Latouche, Aurelien
    Buchholz, Anika
    Schumacher, Martin
    [J]. STATISTICS IN MEDICINE, 2009, 28 (06) : 956 - 971
  • [35] THE HEALTH PROFILE OF MALAYSIAN ADOLESCENTS FROM 1990-2015: A SYSTEMATIC ANALYSIS OF BURDEN OF DISEASE DATA
    Razak, Suraya Abdul
    Sawyer, Susan M.
    Patton, George C.
    Cini, Karly
    Azzopardi, Peter S.
    [J]. JOURNAL OF ADOLESCENT HEALTH, 2018, 62 (02) : S26 - S26
  • [36] Trends in HIV/AIDS morbidity and mortality in Eastern Mediterranean countries, 1990-2015: findings from the Global Burden of Disease 2015 study
    Mokdad, Ali H.
    El Bcheraoui, Charbel
    Wang, Haidong
    Charara, Raghid
    Khalil, Ibrahim
    Moradi-Lakeh, Maziar
    Afshin, Ashkan
    Collison, Michael
    Daoud, Farah
    Chew, Adrienne
    Krohn, Kristopher J.
    Carter, Austin
    Foreman, Kyle J.
    He, Fei
    Kassebaum, Nicholas J.
    Kutz, Michael
    Mirarefin, Mojde
    Nguyen, Grant
    Silpakit, Naris
    Sligar, Amber
    Abajobir, Amanuel Alemu
    Abate, Kalkidan Hassen
    Abbas, Kaja M.
    Abd-Allah, Foad
    Abera, Semaw Ferede
    Adane, Kelemework
    Agarwal, Arnav
    Kiadaliri, Aliasghar Ahmad
    Ahmadi, Alireza
    Ahmed, Muktar Beshir
    Al Lami, Faris Hasan
    Alam, Khurshid
    Alasfoor, Deena
    Alizadeh-Navaei, Reza
    Al-Maskari, Fatma
    Al-Raddadi, Rajaa
    Altirkawi, Khalid A.
    Alvis-Guzman, Nelson
    Ammar, Walid
    Anber, Nahla
    Antonio, Carl Abelardo T.
    Anwari, Palwasha
    Asayesh, Hamid
    Asghar, Rana Jawad
    Atey, Tesfay Mehari
    Avokpaho, Euripide Frinel G. Arthur
    Ayele, Tadesse Awoke
    Azzopardi, Peter
    Bacha, Umar
    Barac, Aleksandra
    [J]. INTERNATIONAL JOURNAL OF PUBLIC HEALTH, 2018, 63 : 123 - 136
  • [37] Burden of Neurological Diseases in Peru 1990-2015: A Systematic Analysis of the Globlal Burden Disease 2015
    Pacheco Barrios, Kevin
    Alva-Diaz, Carlos
    Huerta-Rosario, Andrely
    Navarro-Flores, Alba
    Molina-Nino de Guzman, Roberto
    Mori, Nicanor
    [J]. ANNALS OF NEUROLOGY, 2018, 84 : S81 - S82
  • [38] Trends in the incidence of primary brain, central nervous system and intracranial tumors in Israel, 1990-2015
    Keinan-Boker, Lital
    Friedman, Eitan
    Silverman, Barbara G.
    [J]. CANCER EPIDEMIOLOGY, 2018, 56 : 6 - 13
  • [39] Toxicological findings in suspected drug-impaired drivers in Norway Trends during 1990-2015
    Valen, Anja
    Bogstrand, Stig Tore
    Vindenes, Vigdis
    Gjerde, Hallvard
    [J]. FORENSIC SCIENCE INTERNATIONAL, 2017, 280 : 15 - 24
  • [40] A competing risks analysis of presenting AIDS diagnoses trends
    Fusaro, RE
    Bacchetti, P
    Jewell, NP
    [J]. BIOMETRICS, 1996, 52 (01) : 211 - 225